Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Long-Term Deferred Tax (2019 - 2025)

Vanda Pharmaceuticals' Long-Term Deferred Tax history spans 9 years, with the latest figure at $103.1 million for Q3 2025.

  • For Q3 2025, Long-Term Deferred Tax rose 29.88% year-over-year to $103.1 million; the TTM value through Sep 2025 reached $103.1 million, up 29.88%, while the annual FY2024 figure was $81.4 million, 8.59% up from the prior year.
  • Long-Term Deferred Tax for Q3 2025 was $103.1 million at Vanda Pharmaceuticals, up from $97.1 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $103.1 million in Q3 2025 and bottomed at $67.8 million in Q3 2023.
  • The 5-year median for Long-Term Deferred Tax is $75.3 million (2024), against an average of $78.4 million.
  • The largest annual shift saw Long-Term Deferred Tax decreased 11.89% in 2022 before it increased 29.88% in 2025.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $74.9 million in 2021, then fell by 1.12% to $74.0 million in 2022, then rose by 1.3% to $75.0 million in 2023, then rose by 8.59% to $81.4 million in 2024, then increased by 26.56% to $103.1 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Long-Term Deferred Tax are $103.1 million (Q3 2025), $97.1 million (Q2 2025), and $89.1 million (Q1 2025).